Fairooz Kabbinavar MD
Genitourinary Oncology, Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer
Medical Director of the UCLA Kidney Cancer Program, Associate Professor of Medicine in the Division of Hematology and Oncology in The David Geffen School of Medicine at UCLA, Director of the Hematology/Oncology Fellowship Program in the Division of Hemato
Join to View Full Profile
11055 Flintkote AveSan Diego, CA 92121
Phone+1 310-746-6500
Dr. Kabbinavar is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1986 - 1989
Indira Gandhi Medical CollegeClass of 1979
Certifications & Licensure
MA State Medical License 1989 - 2028
CA State Medical License 1989 - 2027
National Board of Physicians and Surgeons Internal Medicine- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016
- Super Doctor SuperDoctors.com
Clinical Trials
- Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy Start of enrollment: 1999 Nov 01
- Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms Start of enrollment: 1999 Sep 01
- Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 2002 Oct 01
Publications & Presentations
PubMed
- 17 citationsOnvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.Daniel H Ahn, Maya Ridinger, Timothy L Cannon, Lawrence Mendelsohn, Jason S Starr
Journal of Clinical Oncology. 2025-03-01 - 14 citationsPrognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.Romain Cohen, Morteza Raeisi, Benoist Chibaudel, Qian Shi, Takayuki Yoshino
European Journal of Cancer. 2024-08-01 - 36 citationsOnvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.Daniel H Ahn, Afsaneh Barzi, Maya Ridinger, Errin Samuëlsz, Ramanand A Subramanian
Clinical Cancer Research. 2024-05-15
Journal Articles
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerDavid S Shames, Leora Horn, Fairooz Kabbinavar, The New England Journal of Medicine
Press Mentions
Cancer Drug Shortages “Absolutely” On the Horizon Without Interventions, ASCO Executive WarnsJuly 17th, 2025- Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology TreatmentsDecember 18th, 2024
- Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateMarch 2nd, 2023
Other Languages
- Hindi, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
